Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant

Bone Marrow Transplantation

Volumn 40, Issue 8, 2007, Pages 765-772

  Malone, F R ^a   Leisenring, W M ^b,c   Storer, B E ^b,c   Lawler, R ^b   Stern, J M ^b   Aker, S N ^a,b   Bouvier, M E ^b   Martin, P J ^b,d   Batchelder, A L ^b   Schoch, H G ^b   McDonald, G B ^b,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOKINE; GANCICLOVIR; INTERLEUKIN 12; INTERLEUKIN 6; METHOTREXATE; ONDANSETRON; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANOREXIA; ARTICLE; CALORIC INTAKE; CANDIDIASIS; CHILD; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; ENERGY EXPENDITURE; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SIDE EFFECT; STATISTICAL ANALYSIS; VOMITING; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANOREXIA; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTOKINES; ENERGY INTAKE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 34948892867     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705816     Document Type: Article

References (54)

1. Kusnierczyk NM, Saunders EF, Dupuis LL. Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant 2002; 30: 119-124.
2. Lenssen P, Bruemmer B, Aker SN, McDonald GB. Nutrient support in hematopoietic cell transplantation. J Parenter Enteral Nutr 2001; 25: 219-228.
3. Lenssen PA, Aker SN. Chapter 87: Nutritional support of patients with hematologic malignancies. In: Hoffman R, Benz E, Shattil S, Furie B, Cohen HJ, Silberstein L, McGlave P (eds). Hematology Basic Principles and Practice, 4th edn. Elsevier Churchill Livingstone: Philadelphia, 2005, pp 1591-1609.
4. Strasser SI, McDonald GB. Chapter 58: Gastrointestinal and hepatic complications. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell Scientific Publications: Malden, MA, 2004, pp 769-810.
5. Cheney CL, Abson KG, Aker SN, Lenssen P. Cunningham BA, Buergel NS et al. Body composition changes in marrow transplant recipients receiving total parenteral nutrition. Cancer 1987; 59: 1515-1519.
6. Hwang TL, Chiang CL, Wang PN. Parenteral nutrition support after bone marrow transplantation: Comparison of total and partial parenteral nutrition during the early posttransplantation period. Nutrition 2001; 17: 773-775.
7. Muscaritoli M, Conversano L, Torelli GF, Arcese W, Capria S, Cangiano C et al. Clinical and metabolic effects of different parenteral nutrition regimens in patients undergoing allogeneic bone marrow transplantation. Transplantation 1998; 66: 610-616.
8. Papadopoulou A, Williams MD, Darbyshire PJ, Booth IW. Nutritional support in children undergoing bone marrow transplantation. Clin Nutr 1998; 17: 57-63.
9. Epstein RJ, McDonald GB, Sale GE, Shulman HM, Thomas ED. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: A prospective study of thirteen patients. Gastroenterology 1980; 78: 764-771.
10. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-2048.
11. Boeckh M, Fries B, Nichols WG. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 2004; 8 (Suppl 5): 19-27.
12. Gariballa SE, Forster S. Energy expenditure of acutely ill hospitalised patients. Nutr J 2006; 5: 9.
13. Altman PL, Dittmer DS (eds). Metabolism. Federation of American Societies of Experimental Biology: Bethesda, MD, 1968, p 344.
14. Mozaffarian D, Rimm EB, King IB, Lawler RL, McDonald GB, Levy WC. Trans fatty acids and systemic inflammation in heart failure. Am J Clin Nutr 2004; 80: 1521-1525.
15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow transplant 1995; 15: 825-828.
16. McCormack SA, Johnson LR. Role of polyamines in gastrointestinal mucosal growth. Am J Physiol 1991; 260: G795-G806.
17. Binder HJ, Cummings JH, Soergel KH (eds). Falk Symposium 73: Short Chain Fatty Acids. Kluwer Academic Publishers: London, UK, 1994.
18. Mattsson J, Westin S, Edlund S, Remberger M. Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease. Bone Marrow Transplant 2006; 38: 629-633.
19. Banks WA. Anorectic effects of circulating cytokines: Role of the vascular blood-brain barrier. Nutrition 2001; 17: 434-437.
20. Coletti D, Moresi V, Adamo S, Molinaro M, Sassoon D. Tumor necrosis factor-alpha gene transfer induces cachexia and inhibits muscle regeneration. Genesis 2005; 43: 120-128.
21. MohanKumar SM, MohanKumar PS. Systemic interleukin-1beta stimulates the simultaneous release of norepinephrine in the paraventricular nucleus and the median eminence. Brain Res Bull 2005; 65: 451-456.
22. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia-cachexia syndrome: Cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004; 7: 427-434.
23. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-534.
24. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: Relationships between ghrelin and anabolic/ catabolic factors. Circulation 2001; 104: 2034-2038.
25. Plata-Salaman CR. Cytokines and anorexia: A brief overview. Semin Oncol 1998; 25 (Suppl 1): 64-72.
26. Sonti G, Ilyin SE, Plata-Salaman CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol 1996; 270: R1394-R1402.
27. Turrin, NP, Gayle D, Ilyin SE, Flynn MC, Langhans W, Schwartz GJ et al. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res Bull 2001; 54: 443-453.
28. Welsh FK, Farmery SM, MacLennan K, Sheridan MB, Barclay GR, Guillou PJ et al. Gut barrier function in malnourished patients. Gut 1998; 42: 396-401.
29. Fong YM, Marano MA, Barter A, He W, Moldawer LL, Bushman ED et al. Total parenteral nutrition and bowel rest modify the metabolic response to endotoxin in humans. Ann Surg 1989; 210: 449-456.
30. Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 2001; 31: 338-343.
31. Pritts T, Hungness E, Wang Q, Robb B, Hershko D, Hasselgren PO. Mucosal and enterocyte IL-6 production during sepsis and endotoxemia - role of transcription factors and regulation by the stress response. Am J Surg 2002; 183: 372-383.
32. Grotz MR, Deitch EA, Ding J, Xu D, Huang Q, Regel G. Intestinal cytokine response after gut ischemia: Role of gut barrier failure. Ann Surg 1999; 229: 478-486.
33. Moriez R, Salvador-Cartier C, Theodorou V, Fioramonti J, Eutamene H, Bueno L. Myosin light chain kinase is involved in lipopolysaccharide-induced disruption of colonic epithelial barrier and bacterial translocation in rats. Am J Pathol 2005; 167: 1071-1079.
34. Martin PJ, McDonald GB, Sanders JE, Anasetti C, Appelbaum FR, Deeg HJ et al. Increasingly frequent diagnosis of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004; 10: 320-327.
35. Symington FW, Symington BE, Liu PY, Viguet H, Santhanam. U, Sehgal PB. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992; 54: 457-462.
36. Imamura M, Hashino S, Kobayashi H, Kubayashi S, Hirano S, Minagawa T et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant 1994; 13: 745-751.
37. Abdallah AN, Boiron JM, Attia Y, Cassaigne A, Reiffers J, Iron A. Plasma cytokines in graft vs host disease and complications following bone marrow transplantation. Hematol Cell Ther 1997; 39: 27-32.
38. Boussiotis VA, Chen ZM, Zeller JC, Murphy WJ, Berezovskaya A, Narula S et al. Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-beta-treated alloreactive T cells that do not induce graft-versus-host disease. Blood 2001; 97: 565-571.
39. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998; 16: 137-161.
40. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359 693-699.
41. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 1999; 18 1280-1291.
42. Dong Y, Tang L, Letterio JJ, Benveniste EN. The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression. J Immunol 2001; 167: 311-319.
43. Martin CM, Doig GS, Heyland DK, Morrison T, Sibbald WJ. Multicentre, cluster-randomized clinical trial of algorithms for critical-care enteral and parenteral therapy (ACCEPT). Cmaj 2004; 170: 197-204.
44. Taylor SJ, Fettes SB, Jewkes C, Nelson RJ. Prospective, randomized, controlled trial to determine the effect of early enhanced enteral nutrition on clinical outcome in mechanically ventilated patients suffering head injury. Crit Care Med 1999; 27: 2525-2531.
45. Nishimoto N, Sasai M, Shimia Y, Nakagawa M, Matsumoto T, Shirai T et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95 56-61.
46. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D et al. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330: 602-605.
47. D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2006; 8: 506-512.
48. Pignatti P, Vivarelli M, Meazza C, Rizzolo MG, Martini A, De Benedetti F. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol 2001; 28: 1670-1676.
49. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003; 30: 1426-1435.
50. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46: 3143-3150.
51. Haddad E, Paczesny S, Leblond V, Seigneurin JM, Stern M, Achkar A et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial. Blood 2001; 97: 1590-1597.
52. Trikha M, Corringham R, Klein B, Rossi J-F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-4665.
53. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 2000; 109: 661-664.
54. Kishimoto T, Tanaka T, Yoshida K, Akira S, Taga T. Cytokine signal transduction through a homo- or heterodimer of gp130. Ann N Y Acad Sci 1995; 766: 224-234.